Olaparib: beside an established treatment under test
21 studies: an approved drug, surgery or radiation is what the study tests. Page 1 of 1. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.
- Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus ChemotherapyNot yet recruitingNCT07486687Phase 3Report a problem
- CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate CancerNot yet recruitingNCT07268794Phase 2Report a problem
- NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast CancerNot yet recruitingNCT07178730Phase 3Report a problem
- Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate CancerRecruitingNCT06585007Phase 3Report a problem
- Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)RecruitingNCT06401980Phase 2Report a problem
- PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBCRecruitingNCT06245889Phase 2Report a problem
- Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast CancerRecruitingNCT06201234Phase 2Report a problem
- Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast CancerRecruitingNCT06197581Not applicableReport a problem
- Telmisartan in Prostate CancerRecruitingNCT06168487Phase 1Report a problem
- Metastasis-directed Therapy for Oligometastases of Breast CancerRecruitingNCT06135714Phase 3Report a problem
- Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate CancerRecruitingNCT05406999Phase 2Report a problem
- Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast CancerRecruitingNCT05345860Not applicableReport a problem
- Olaparib with or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based ChemotherapyRecruitingNCT05222971Phase 2Report a problem
- Surgery Combined with Maintenance Targeted Therapy in the Treatment of Advanced Ovarian CancerRecruitingNCT05200260Phase 2Report a problem
- WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOCRecruitingNCT04644289Phase 2Report a problem
- Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian CancerRecruitingNCT04633239Phase 1Report a problem
- Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected MutationsActive, not recruitingNCT03842228Phase 1Results postedReport a problem
- Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)CompletedNCT03167619Phase 2Results postedReport a problem
- Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment TrialWithdrawnNCT05967286Phase 2Report a problem
- Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA MutationsActive, not recruitingNCT04548752Phase 2Report a problem
- Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast CancerActive, not recruitingNCT02849496Phase 2Report a problem